KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $12.1 million.

  • Castle Biosciences' Share-based Compensation fell 7.12% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 9.39%. This contributed to the annual value of $50.3 million for FY2024, which is 1.76% down from last year.
  • As of Q3 2025, Castle Biosciences' Share-based Compensation stood at $12.1 million, which was up 7.96% from $11.2 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Share-based Compensation high stood at $13.5 million for Q1 2023, and its period low was $4.8 million during Q2 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $12.7 million (2024), whereas its average is $12.4 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 211.54% in 2021, then dropped by 14.96% in 2025.
  • Castle Biosciences' Share-based Compensation (Quarterly) stood at $6.9 million in 2021, then spiked by 44.84% to $9.9 million in 2022, then climbed by 18.94% to $11.8 million in 2023, then decreased by 3.08% to $11.4 million in 2024, then declined by 7.12% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q3 2025, $11.2 million for Q2 2025, and $11.2 million during Q1 2025.